Weekly Recap: FY26 loss and Consumer Health sale, U.S. mfg move
Aytu BioPharma, Inc. (NASDAQ:AYTU) reported fiscal 2026 revenue of $57.57M and a $14.25M net loss while reshaping its business—selling Consumer Health, winding down non—core trials and shifting Adzenys/Cotempla manufacturing—as it boosts EXXUA promotion and sustains ADHD product availability amid a…